338 related articles for article (PubMed ID: 4257720)
1. [Therapy of spastic syndromes].
Hartmann-von Monakow K
Bibl Psychiatr Neurol; 1969; 139():114-23. PubMed ID: 4257720
[No Abstract] [Full Text] [Related]
2. [Therapeutic possibilities in spasticity. Review].
Roşianu C
Neurol Psihiatr Neurochir; 1971; 16(1):59-70. PubMed ID: 4253575
[No Abstract] [Full Text] [Related]
3. Centrally acting skeletal-muscle relaxants.
Domino EF
Arch Phys Med Rehabil; 1974 Aug; 55(8):369-73. PubMed ID: 4850933
[No Abstract] [Full Text] [Related]
4. The use of drugs in the treatment of spasticity.
Lenman JA
Proc R Soc Med; 1970 Sep; 63(9):935-7. PubMed ID: 5477076
[No Abstract] [Full Text] [Related]
5. [Central acting muscle relaxants].
Nilsson S
Tidsskr Nor Laegeforen; 1974 Sep; 94(27):1660-4. PubMed ID: 4424879
[No Abstract] [Full Text] [Related]
6. [Neuroleptics, thymoleptics and tranquilizers in neurological therapy].
Hertrich O
Bibl Psychiatr Neurol; 1969; 139():88-113. PubMed ID: 4400242
[No Abstract] [Full Text] [Related]
7. Clinical assessment and pharmacologic therapy of spasticity.
Pedersen E
Arch Phys Med Rehabil; 1974 Aug; 55(8):344-54. PubMed ID: 4277407
[No Abstract] [Full Text] [Related]
8. [MEDICAL TREATMENT OF SPASTICITY].
PEDERSEN E
Nord Med; 1964 Jan; 71():17-20. PubMed ID: 14103689
[No Abstract] [Full Text] [Related]
9. A controlled clinical trial of chlormezanone, orphenadrine, orphenadrine/paracetamol and placebo in the treatment of painful skeletal muscle spasms.
Valtonen EJ
Ann Clin Res; 1975 Apr; 7(2):85-8. PubMed ID: 1103709
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of the characteristics of the effect of tranquilizing agents under experimental and clinical conditions].
Vikhliaev IuI; Klygul' TA; Prokudin VN; Adronati SA
Farmakol Toksikol; 1971; 34(1):30-5. PubMed ID: 5563373
[No Abstract] [Full Text] [Related]
11. [Muscle relaxants in the treatment of idiopathic trigeminal neuralgia (author's transl)].
von Albert HH
MMW Munch Med Wochenschr; 1975 Aug; 117(35):1379-82. PubMed ID: 809678
[TBL] [Abstract][Full Text] [Related]
12. [Muscle relaxants. 4].
Horn W
Pharm Prax; 1967; 5():124-30. PubMed ID: 4885114
[No Abstract] [Full Text] [Related]
13. [The basic criteria for clinical evaluation of the effect of tranquilizers].
Aleksandrovskiĭ IuA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(12):1873-82. PubMed ID: 5511527
[No Abstract] [Full Text] [Related]
14. [COMPLARATIVE CHARACTERISTICS OF THE CLINICAL EFFECTS OF TRANQUILIZERS].
Aleksandrovskiĭ IuA; But PG; Kaplunskiĭ GD; poltorakov AP; Chibrikin VM
Zh Nevropatol Psikhiatr Im S S Korsakova; 1974; 74(9):1389-97. PubMed ID: 4154099
[No Abstract] [Full Text] [Related]
15. Management of spasticity on neurophysiological basis.
Pedersen E
Scand J Rehabil Med Suppl; 1980; 7():68-79. PubMed ID: 6448477
[No Abstract] [Full Text] [Related]
16. Medical treatment of spasticity.
Delaney JF
Curr Probl Surg; 1980 Apr; 17(4):245-8. PubMed ID: 6892798
[No Abstract] [Full Text] [Related]
17. Evaluation of a combined muscle relaxant-analgesic as an effective therapy for painful skeletal muscle spasm.
Scheiner JJ
Curr Ther Res Clin Exp; 1972 Apr; 14(4):168-77. PubMed ID: 4623596
[No Abstract] [Full Text] [Related]
18. [Myotonolysis by means of orphenadrine citrate. Clinical and electromyographic studies in cerebral and spinal spasticity].
Steinbrecher W
Arzneimittelforschung; 1966 Feb; 16(2):147-53. PubMed ID: 6014007
[No Abstract] [Full Text] [Related]
19. [Results of the clinical experimentation with CB 4261 (Tetrazepam) affecting spasticity in neurologic diseases. Use of secondary effects (56 cases)].
Turon R; Lagrave F
Bord Med; 1970 Sep; 3(9):2193-204. PubMed ID: 5481197
[No Abstract] [Full Text] [Related]
20. Dantrolene sodium: long-term effects in patients with muscle spasticity.
Joynt RL
Arch Phys Med Rehabil; 1976 May; 57(5):212-7. PubMed ID: 776122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
